MEDI3250

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Healthy Japanese Children Age 2 Years Through 6 YearsHealthy Japanese Children Age 7 Years Through 18 Years

Phase 3

A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years

CompletedNCT02269488

AstraZenecaHealthy Japanese Children Age 2 Years Through 6 Years

Start: 2014-11-30End: 2015-02-28Updated: 2015-09-28

A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years

CompletedNCT02269475

AstraZenecaHealthy Japanese Children Age 7 Years Through 18 Years

Start: 2014-10-31End: 2015-04-30Updated: 2017-04-04